Business Model Breakdown
How Nuvation Bio Inc Makes Money
NUVB
Market Cap
$1.6B
Annual Revenue
$63M
Profit Margin
-325.3%
Employees
291
The Short Version
Nuvation Bio is a clinical-stage and newly commercial-stage biotechnology company focused on discovering, developing, and commercializing innovative precision oncology therapies for patients with difficult-to-treat cancers. The company's primary revenue source is currently through the direct sales of its FDA-approved drug, IBTROZI® (taletrectinib), used for treating ROS1-positive non-small cell lung cancer. As it expands globally and advances its pipeline, Nuvation Bio aims to generate additional revenue from new product launches and licensing agreements, targeting significant unmet medical needs in oncology.
Where the Revenue Comes From
IBTROZI® (Taletrectinib) product sales (~100% of current reported revenue)
Who buys: Oncology patients diagnosed with specific genetic mutations (e.g., ROS1+ NSCLC), and the oncologists who prescribe the company's approved therapies.
Why It Works (Competitive Advantages)
- ✔First-mover advantage and differentiated profile for taletrectinib in ROS1+ NSCLC post-FDA approval.
- ✔Experienced leadership team with a strong track record in oncology drug development (Dr. David Hung).
- ✔Broad and diversified precision oncology pipeline beyond taletrectinib.
Economic Moat: Narrow (Intangible Assets/IP (patent protection for taletrectinib and pipeline compounds))
What Our Analysis Says
DVR Score as of April 12, 2026
Nuvation Bio (NUVB) sustains its high 10x growth potential, reflecting robust progress in its transformation to a commercial-stage oncology firm. The Q4 2025 revenue beat and initial IBTROZI® product revenue of $24.7M with 216 new patient starts validate its commercial launch. Furthermore, the EMA's validation of taletrectinib's marketing application and upcoming pivotal data presentation at AACR highlight significant catalysts for market expansion and re-rating. While deep unprofitability and a high cash burn persist, these developments strengthen NUVB's competitive positioning and future market leadership, justifying a slight score increase to acknowledge the confirmed execution and pipeline advancements.